HealthCore presents ISPOR poster sessions

The verbal presentations are scheduled as follows:

SESSION I / Monday, May 23 / 8 a.m. - 8:30 p.m.

PCV106

Re-Hospitalization Rates of Acute Coronary Syndrome Patients in Real World Clinical Practice: Observations from a National Administrative Claims Data

Tunceli O1, Gandhi SK2, Bhandary D2, Stephenson JJ1, Gold A2, Fu AC1, Kern DM1, Singer J1
1HealthCore, Inc., Wilmington, Del.; 2AstraZeneca Pharmaceuticals LP, Wilmington, Del.

SESSION II / Tuesday, May 24 / 8 a.m. - 7:45 p.m.

PIN6

Trends of Hepatitis A Incidence from 2005 to 2008

Eisenberg D1, Changolkar AK2, Misurski DA2
1HealthCore, Inc., Wilmington, Del.; 2GlaxoSmithKline, Philadelphia, Pa.

PRS42

Concomitant Asthma Medication Use in Patients Using Omalizumab: Results from Three Large Insurance Claims Databases

Lafeuille MH1, Duh MS2, Zhang J3, Wertz D4, Gu T4, Tang J2, Lefebvre P1

1Groupe d'analyse, Ltée, Montreal, Canada; 2Analysis Group, Inc., Boston, Mass; 3Novartis Pharmaceuticals Corporation, East Hanover, N.J/; 4HealthCore, Inc., Wilmington, Del.

SESSION III / Wednesday, May 25 / 8 a.m. - 3 p.m.

PCN100

Racial Disparities in African-American Versus White Women with Newly Diagnosed Breast Cancer in a Southeast United States Health Plan

Fisher M1, Cai Q1, Paoli CJ2, Lyons A3, Wasser T1, Rodriguez N4, White S5, Kallich J3, Barron J1, Brawley OW6

1HealthCore, Inc., Wilmington, Del.,; 2University of California, San Francisco, San Francisco, Calif.; 3Amgen, Inc., Thousand Oaks, Calif.; 4Blue Cross Blue Shield of Georgia, Atlanta, Ga., 5WellPoint, Atlanta, Ga; 6American Cancer Society, Atlanta, Ga.

PGI2

Predictors of Proton Pump Inhibitor (PPI) Dosing Regimen Among Patients with Gastroesophageal Reflux Disease (GERD)

Eisenberg D1, Mody R2, Singer J1, Kamat SA1, Gerson LB3

1HealthCore, Inc., Wilmington, Del; 2Takeda Pharmaceuticals International, Inc., Deerfield, Ill.; 3Stanford University, Palo Alto, Calif.

PMH30

Indirect Costs (IC) of Adult Women with Anxiety Disorders (AD) in the United States in 2006 from the Medical Expenditures Panel Survey (MEPS)

Kavati A1, Rappaport H2

1HealthCore, Inc., Wilmington, Del; 2University of Louisiana at Monroe, Monroe, La.

PMH71

Health Care Resource Utilization (HCRU) and Direct Medical Expenditures (DME) for Adult Women with Anxiety Disorders (AD) in the United States in 2006 from the Medical Expenditures Panel Survey (MEPS)

Kavati A1, Rappaport H2

1HealthCore, Inc., Wilmington, Del.; 2University of Louisiana at Monroe, Monroe, La.

PMH78

Persistence of Stimulant Treatment in Children and Adolescents with Attention-Deficit Hyperactivity Disorder

Palli SR1, Aparasu RR2, Chen H2, Sherer JT2

1HealthCore, Inc., Wilmington, Del; 2University of Houston, Houston, Texas.

PMH79

Psychotropic Polypharmacy in Children and Adolescents with Attention - Deficit / Hyperactivity Disorder

Palli SR1, Aparasu RR2, Chen H2, Sherer JT2

1HealthCore, Inc., Wilmington, Del; 2University of Houston, Houston, Texas.

PND36

Internal Locus of Control and Treatment Satisfaction with Natalizumab

Stephenson JJ1, KernDM1, Agarwal SS2, Kamat SA1

1HealthCore, Inc., Wilmington, Del.; 2Biogen Idec Inc., Weston, Mass.

PND39

Multiple Sclerosis Patients Report Improvements in Fatigue and Cognitive Functioning After One Year of Natalizumab Treatment

Stephenson JJ1, Kern DM1, Agarwal SS2, Kamat SA1

1HealthCore, Inc., Wilmington, Del.; 2Biogen Idec Inc., Weston, Mass.

PND45

One Year of Natalizumab Treatment is Associated with an Improvement in Health-related Quality of Life in Multiple Sclerosis Patients

Stephenson JJ1, Kern DM1, Agarwal SS2, Kamat SA1

1HealthCore, Inc., Wilmington, Del.; 2Biogen Idec Inc., Weston, Mass.

Provided by HealthCore